Current Drug Scheduling Reviews Reported by DEA
The FASEB Journal April 1, 2009 Sandy Ghozland, Srihari R. Tella, Michelle D. Walker et al.
Pursuant to the Controlled Substances Act (CSA), DEA collects and reviews scientific, medical and other data for substances with abuse potential for possible placement under the CSA. The administrative process for scheduling is ongoing for indiplon, carisoprodol, dextromethorphan, salvinorin A and several petitions requesting a change in the control status of nabilone, methylphenidate product,...